



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/519,598	09/23/2005	Thomas J. Guttuso Jr	176/61332	7385
7590	08/03/2006			EXAMINER GEMBEH, SHIRLEY V
Edwin V Merkel Nixon Peabody Clinton Square PO Box 31051 Rochester, NY 14603			ART UNIT 1614	PAPER NUMBER
DATE MAILED: 08/03/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/519,598	GUTTUSO JR, THOMAS J.	
	Examiner	Art Unit	
	Shirley V. Gembeh	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-20, 47 and 48 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-20, 47 and 48 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>12/27/04</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Information Disclosure Statement

The information disclosure statement (IDS) submitted on December 27, 2004 has been received and acknowledged.

Specification

The amendment to the specification has been received and the disclosure to the claims claiming priority to the application (national stage application) under 35 U.S.C. § 371 from PCT Application No. PCT US 2003/021785, filed July 14, 2003, which claims the priority benefit of U.S. Provisional Patent Application No. 60/395,975, filed July 12, 2002 has been acknowledged and entered.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-20 and 47-48 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product

claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" for the "activity of endogenous ligands" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of

Art Unit: 1614

only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

In other words, the Applicant has not described with sufficient clarity what is the endogenous ligands.

II. Claims 18 and 19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" for the "organoleptically suitable carrier" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of

only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

In other words, the Applicant has not described with sufficient clarity what the organoleptically suitable carrier is or are.

III. Claims 1-19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" for the "symptom of hormonal variation" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to

that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

In other words, the Applicant has not described with sufficient clarity what the symptom of hormonal(s) variation is or are. In order to overcome this rejection Examiner suggest the inclusion of at least one of the symptoms in claim 20 in claim 1.

III. The following is a quotation of the second paragraph of 35 U.S.C. 112: Second

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1 and dependant claims 14-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The last line of claim 1 recites that the compound is not L-leucine, but line 5 of claim 1 includes L-leucine and so does claim 6. Is L-leucine included or not.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3, 14-17 and 20 are rejected under 35 U.S.C. 102(b) as being anticipated by Gollobin, US 5,789,443.

Gollobin teach administering to a patient suffering from the condition- hot flash an amount of L-leucine (see abstract and also col. 4 line 60) as in claims 1 and 20, and L-isoleucine as in instant claim 3 (see col.3 lines 50+ and also col. 4 line 60). The Gollobin reference also teaches with regards to claim 14-17, the compound administered in the amount 250-1000 mg/day (see col. 4, lines 33+) as in claim 14, administered orally (see col. 4, lines 17+) as in claim 15, in an acceptable pharmaceutical carrier (see col. 4, lines 45+) as in claim 16 wherein the claimed compound is in a liquid or solid dosage form as in claim 17 (see col. 4 lines 15+). With regards to symptoms that can be alleviated by interfering with the activity of endogenous ligands on the $\alpha_2\beta$ subunit of a voltage gated calcium channel is anticipated as endogenous substances are those that originate from within an organism, tissue or cell.

Claims 47-48 are rejected under 35 U.S.C. 102(b) as being anticipated by Gollobin, US 5,789,443.

Gollobin teaches a pharmaceutical composition/formulation used for the treatment of hot flash, (alleviated by interfering with the activity of endogenous ligands on the $\alpha_2\beta$ subunit of a voltage gated calcium channel) comprising L-leucine in a capsule (thus a single dosage form) (see col. 4, lines 59+) comprising L-isoleucine. Also teaches the capsule comprises of two or more compounds (see col. 4, lines 59+).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-6, 14-17 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gollobin, US 5,789,443 taken with Henry et al. WO 01/68069 taken with Paul US patent 6,149,924.

Gollobin teach administering to a patient suffering from the condition- hot flash an amount of L-leucine (see abstract and also col. 4 line 60) as in claims 1 and 20, and L-isoleucine as in instant claim 3 (see col.3 lines 50+ and also col. 4 line 60). The Gollobin reference also teaches with regards to claim 14-17, the compound administered in the amount 250-1000 mg/day (see col. 4, lines 33+) as in claim 14, administered orally (see col. 4, lines 17+) as in claim 15, in an acceptable pharmaceutical carrier (see col. 4, lines 45+) as in claim 16 wherein the claimed compound is in a liquid or solid dosage form as in claim 17 (see col. 4 lines 15+).

Henry et al. teaches methods for treating cough or asthma comprising administering Methionine as in current claim 5.

Paul teaches norleucine, alloisoleucine and leucine (see col. 3, lines 33-55) as in claims 1- 4 and 6.

One of ordinary skill in the art would combine the teachings of Gollobin taken with Henry et al. and Paul to treat a conditions characterized by symptoms that can be

Art Unit: 1614

alleviated by endogenous ligands because the art teaches the use of these amino acids for the treatment of hot flash, asthma and cough.

Thus one of skill in the art would be motivated at the time the claimed invention was made to use the teachings of the above cited references to treat conditions characterized by symptoms that can be alleviated by endogenous ligands.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/519,598
Art Unit: 1614

Page 10

SVG
7/26/06

Ardin H. Marschel 7/30/06
ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER